Supriya Lifescience Limited (SUPRIYA)
Micro CapPharma stocks · Micro cap · NSE
Supriya Lifescience is a global API manufacturer specializing in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthmatics, and Anesthetics. It offers 40+ APIs, operates in over 120 countries, and generated 82% of its FY26 revenue from exports.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Mixed fundamentals, management trust is supportive, price trend is neutral, and recent execution is mixed.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 30 Jun 2026
Bad · 0/100PAT -31% YoY · margin compression · Rev +31% YoY
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹190 Cr | +31.0% | -31.4% |
| EBITDA | ₹47 Cr | -9.6% | -52.0% |
| Operating margin | 25.0% | -1100 bps | -1000 bps |
| PAT | ₹24 Cr | -31.4% | -67.6% |
| PAT margin | 12.6% | -1151 bps | -1408 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Where growth can come from, and what can break the case
Supriya Lifescience reported strong Q4FY26 revenue growth of 50% YoY to INR 2,765.3 Mn, with PAT up 47% YoY to INR 742.3 Mn. For FY26, revenue grew 19% YoY to INR 8,278.7 Mn, and PAT increased 11% YoY to INR 2,091.2 Mn, though margins compressed.
The company delivered robust revenue and profit growth in Q4 and FY26, driven by new product launches and strong export performance. However, EBITDA and PAT margins saw YoY compression. Ongoing capacity expansion, R&D focus, and backward integration efforts are positive, but margin sustainability requires close monitoring.
New Product Development
Ongoing efforts to add 3-4 products every year, with 30 products under development in Finished Dosage R&D.
Geographic Expansion
Penetration of existing products to newer geographies by registering them and expanding customer base in Japan, EU, and US.
CMO/CDMO Opportunities
Multiple opportunities under active negotiation for finished dosage development and supply, with a recently added Kilolab.
Capacity Enhancement
New vitamin product block successfully commissioned, and civil work initiated for debottlenecking and a new F block.
New Vitamin Product Block
New vitamin product block successfully commissioned.
Debottlenecking & New Block
Civil work initiated for debottlenecking across all production blocks for capacity enhancement and a new F block will be added.
Finished Dosage Lines
Five finished dosage manufacturing lines are operational.
New Production Block at Lote
Capacity expansion planned with the addition of a new production block at Lote.
Backward Integration
76% of FY26 revenue from backward integrated products, which management claims enables revenue growth while sustaining margins.
Diversified Global Presence
Presence in 120+ Countries Across Globe with 82% of FY26 revenue from exports, reducing specific geography dependence.
Strong R&D Focus
A team of 68 scientists primarily focused on API and formulations process development, with two patents filed this year.
Management accountability
What management said, and what results must prove
Management accountability
What management said, and what results must prove
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
The company operates in a global API market which can have seasonal demand patterns, making YoY comparison essential for underlying performance. QoQ comparison is also relevant to assess sequential momentum from new product launches and capacity ramp-ups.
Export Revenue Contribution
82% FY26 Revenue from exports.
Q4FY26 EBITDA Margin
EBITDA % was 35.3%, a decrease of 141 bps YoY.
FY26 EBITDA Margin
EBITDA % was 35.5%, a decrease of 192 bps YoY.
New Product Launches
FY26 Product Updates included Cardio Vascular, ADHD, and Liquid Anesthetic launches. FY27 Pipeline plans ~2 launches each in Anesthetic and ADHD.
Customer Concentration Reduction
Management plans to further reduce customer concentration from the current 52% from top 10 customers.
Product Pipeline Expansion
Management states ongoing efforts to add 3-4 products every year and plans to file six dossiers in the EU during the current financial year.
Strategic Partnerships
GLP-1 portfolio development and supply is in progress for a leading Indian generics company, and discussions are ongoing with an innovator partner.
Market Expansion
Regulatory filings in EU and US are underway to enable long-term contracts and market expansion.
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| EBITDA Margin | 35.5% (FY26) | Stability or improvement in margins, especially given recent compression. |
| New Product Launches | 3-4 products annually planned | Timely execution of planned launches and their revenue contribution. |
| Customer Concentration | 52% of FY26 revenue from top 10 customers | Progress in reducing dependence on top customers. |
| Capacity Utilization & Ramp-up | Healthy utilization, new blocks commissioned/planned | Specific utilization rates and revenue contribution from new capacities. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trend score and candlestick chart
57NeutralSMA20 -5.4% / mo · MACD + · sector +2.2pp vs Nifty (3M)
Technical chart
SUPRIYAdaily · 1Y · AUTO+36.6%Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 56. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~5.7% over last month) — short-term momentum negative.
- RSI(14) at 56 — rising, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- 21% off 52W high · 56% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & score drivers
U-Score 53 · FAIR VALUE · pillar breakdown, sector model, fair-value anchor
Valuation & score drivers
U-Score 53 · FAIR VALUE · pillar breakdown, sector model, fair-value anchor
Fundamental score breakdown
FAIR VALUEWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 21.3%.
- Balance sheet contributes 11/15 to the score.
Main drags
- Valuation is weaker at 5/30; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
- Growth is weaker at 14/25; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: -2 points.
Factor attribution
Modelled fair value
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Healthy Trust: Claim history is still being built. It ranks around the 97th percentile of the scored universe and 95th percentile within Pharma. No major sub-score weakness stands out.
High Trust Lite: Promoter holding is 68.3%. Key concern: 1 of the latest 4 quarters had PAT decline worse than 25% YoY.
Generally investable credibility. Look for weak sub-scores before increasing position size.
overall median 67 · Pharma: 95th pctile, median 70 · Micro: 95th pctile, median 73
75 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Healthy Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 68.3%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.2%.
- ▸5 years of positive FCF.
Trust risks
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Fundamentals
Valuation
- P/E
- 32.60
- P/B
- 5.40
- EV/EBITDA
- 20.21
- Market Cap
- 6482.00Cr
Profitability
- ROE
- 19.10%
- ROCE
- 25.10%
- ROA
- 14.59%
- Dividend Y
- 0.12%
Growth (CAGR)
- Revenue 5Y
- 16.00%
- EPS 5Y
- 11.00%
- Revenue 3Y
- 22.00%
- EPS 3Y
- 33.00%
Balance Sheet
- Debt/Equity
- 0.00
- Interest Coverage
- 145.00×
- Altman Z
- 8.89
- Book Value
- 149.00
Cash Flow
- FCF Yield
- 0.20%
- FCF Positive Y
- 5/5
- OCF
- 165.00 Cr
- EPS TTM
- 24.65
Shareholding
- Promoter Hold
- 68.30%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 48%
Financial History
Updated 5/9/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.